The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Tnfrsf11b  -  tumor necrosis factor receptor superfamily...

Rattus norvegicus

Synonyms: Opg, Osteoprotegerin, Tumor necrosis factor receptor superfamily member 11B
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tnfrsf11b


High impact information on Tnfrsf11b

  • Morphometric analysis revealed that the addition of PTH to PEG sTNFRI or OPG resulted in higher bone volume and higher osteoblast numbers in both AIA and CIA [5].
  • Analysis of bone erosion revealed a significant bone-sparing effect of monotherapy with PEG sTNFRI or OPG in both models, whereas IL-1Ra was only effective in CIA [5].
  • Osteoprotegerin (a decoy receptor for RANK ligand) did not significantly alter the effects of UDP on NF-kappaB localization or osteoclast survival, consistent with a direct action [6].
  • A decoy receptor for RANKL, osteoprotegerin, (OPG) impinges on this system and regulates osteoclast numbers and activity [1].
  • After induction of CIA in Dark Agouti rats, test animals were treated with or without Fc-OPG (3 mg/kg/day) subcutaneously for 5 days, beginning at the onset of disease [1].

Chemical compound and disease context of Tnfrsf11b

  • In this study we show that the inhibition of bone resorption by treatment with the hormone calcitonin, the cytokine osteoprotegerin, or the drug alendronate, completely inhibits the generation of the fetuin-mineral complex in response to etidronate injection [7].
  • Therefore, we conclude that doses of osteoprotegerin that inhibit bone resorption are able to potently inhibit the calcification of arteries that is induced by warfarin treatment and by vitamin D treatment [8].

Biological context of Tnfrsf11b

  • Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption [9].
  • Previous studies had shown that PKC-alpha gene expression is downregulated at the time (Day 3) that OPG expression is downregulated [4].
  • CONCLUSIONS: In the early stages of arthritis, synovial RANKL is closely involved in osteoclastogenesis, and various changes in synovial cytokines, including down-regulation of OPG, probably accelerate osteoclast formation [10].
  • To test this hypothesis, we examined the effects of substrate microarchitecture on production of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL), which have been identified as a key regulatory system of bone remodeling [11].
  • Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars [12].

Anatomical context of Tnfrsf11b


Associations of Tnfrsf11b with chemical compounds

  • Immunohistochemical observation also showed that 2,2'-(hydroxynitrosohydrazino)bis-ethanamine increased OPG expression of osteochondral cells located at metaphyseal endosteum and calcified cartilage of proximal femurs in ovariectomized rats [14].
  • We further show that phorbol myristate acetate, an activator of protein kinase C, activated the secretion of OPG [15].
  • MATERIALS AND METHODS: Osteogenic differentiation was induced in hMSCs cultured in maintenance medium (MM) by addition of ascorbate, beta-glycerophosphate, and dexamethasone (ODM) and was assessed by measuring alkaline phosphatase activity, expression of osteopontin, osteoprotegerin, RANKL, and mineralization [16].
  • The ORX-induced increase in urinary deoxypyridinoline (DPD) excretion was completely prevented by all doses of dried plum coinciding with down-regulation of gene expression for receptor activator of NFkappa-B ligand (RANKL) and osteoprotegerin (OPG) in the bone [17].
  • Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats [18].

Regulatory relationships of Tnfrsf11b

  • Injection of phorbolmyristate acetate (PMA), an activator of protein kinase C (PKC) that in turn upregulates OPG expression, also delayed eruption by 1 day [4].

Other interactions of Tnfrsf11b

  • The co-expression of OPG and RANKL in the same bone cell types confirms their strictly coupled action in the regulation of bone metabolism [13].
  • In the bone marrow, RT-PCR did not clearly detect the expression of IL-6, RANKL or OPG mRNA [10].
  • RESULTS: When given acutely, both E(2) and the CR extract inhibited LH secretion and slightly stimulated gene expression of IGF-I, collagen-1alpha1, osteoprotegerin and osteocalcin (all osteoblast products), and of tartrate-resistant acid phosphatase (TRAP, an osteoclast product) in the metaphysis of the femur [19].

Analytical, diagnostic and therapeutic context of Tnfrsf11b


  1. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Romas, E., Sims, N.A., Hards, D.K., Lindsay, M., Quinn, J.W., Ryan, P.F., Dunstan, C.R., Martin, T.J., Gillespie, M.T. Am. J. Pathol. (2002) [Pubmed]
  2. Immune response: the key to bone resorption in periodontal disease. Taubman, M.A., Valverde, P., Han, X., Kawai, T. J. Periodontol. (2005) [Pubmed]
  3. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E., Geng, Z., Tan, H.L., Dunstan, C., Lacey, D., Martin, D. Calcif. Tissue Int. (2006) [Pubmed]
  4. Injections of osteoprotegerin and PMA delay tooth eruption. Wise, G.E., Yao, S., Liu, D. Clinical anatomy (New York, N.Y.) (2006) [Pubmed]
  5. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Schett, G., Middleton, S., Bolon, B., Stolina, M., Brown, H., Zhu, L., Pretorius, J., Zack, D.J., Kostenuik, P., Feige, U. Arthritis Rheum. (2005) [Pubmed]
  6. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. Korcok, J., Raimundo, L.N., Du, X., Sims, S.M., Dixon, S.J. J. Biol. Chem. (2005) [Pubmed]
  7. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. Price, P.A., Caputo, J.M., Williamson, M.K. J. Bone Miner. Res. (2002) [Pubmed]
  8. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Price, P.A., June, H.H., Buckley, J.R., Williamson, M.K. Arterioscler. Thromb. Vasc. Biol. (2001) [Pubmed]
  9. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. Wise, G.E., Yao, S., Zhang, Q., Ren, Y. Arch. Oral Biol. (2002) [Pubmed]
  10. Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis. Kishimoto, Y., Fukumoto, S., Nishihara, S., Mizumura, H., Hirai, K., Teshima, R. Rheumatology (Oxford, England) (2004) [Pubmed]
  11. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer, S., Schwartz, Z., Wang, L., Lohmann, C.H., Turner, J.D., Wieland, M., Cochran, D.L., Boyan, B.D. Journal of biomedical materials research. Part A. (2004) [Pubmed]
  12. Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. Low, E., Zoellner, H., Kharbanda, O.P., Darendeliler, M.A. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. (2005) [Pubmed]
  13. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. Silvestrini, G., Ballanti, P., Patacchioli, F., Leopizzi, M., Gualtieri, N., Monnazzi, P., Tremante, E., Sardella, D., Bonucci, E. J. Mol. Histol. (2005) [Pubmed]
  14. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. Wang, F.S., Wang, C.J., Chen, Y.J., Huang, Y.T., Huang, H.C., Chang, P.R., Sun, Y.C., Yang, K.D. Endocrinology (2004) [Pubmed]
  15. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. Yang, X., Halladay, D., Onyia, J.E., Martin, T.J., Chandrasekhar, S. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
  16. Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. Zahanich, I., Graf, E.M., Heubach, J.F., Hempel, U., Boxberger, S., Ravens, U. J. Bone Miner. Res. (2005) [Pubmed]
  17. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Franklin, M., Bu, S.Y., Lerner, M.R., Lancaster, E.A., Bellmer, D., Marlow, D., Lightfoot, S.A., Arjmandi, B.H., Brackett, D.J., Lucas, E.A., Smith, B.J. Bone (2006) [Pubmed]
  18. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. Miyazaki, T., Matsunaga, T., Miyazaki, S., Hokari, S., Komoda, T. J. Cell. Biochem. (2004) [Pubmed]
  19. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Seidlova-Wuttke, D., Hesse, O., Jarry, H., Christoffel, V., Spengler, B., Becker, T., Wuttke, W. Eur. J. Endocrinol. (2003) [Pubmed]
  20. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. Malyankar, U.M., Scatena, M., Suchland, K.L., Yun, T.J., Clark, E.A., Giachelli, C.M. J. Biol. Chem. (2000) [Pubmed]
WikiGenes - Universities